FR22C1063I2 - THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF HIV VIRUS INFECTION - Google Patents
THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF HIV VIRUS INFECTIONInfo
- Publication number
- FR22C1063I2 FR22C1063I2 FR22C1063C FR22C1063C FR22C1063I2 FR 22C1063 I2 FR22C1063 I2 FR 22C1063I2 FR 22C1063 C FR22C1063 C FR 22C1063C FR 22C1063 C FR22C1063 C FR 22C1063C FR 22C1063 I2 FR22C1063 I2 FR 22C1063I2
- Authority
- FR
- France
- Prior art keywords
- therapeutic
- prophylactic
- virus infection
- compounds useful
- hiv virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001225 therapeutic effect Effects 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377312P | 2016-08-19 | 2016-08-19 | |
| US201762457555P | 2017-02-10 | 2017-02-10 | |
| PCT/US2017/047416 WO2018035359A1 (en) | 2016-08-19 | 2017-08-17 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR22C1063I1 FR22C1063I1 (en) | 2023-02-03 |
| FR22C1063I2 true FR22C1063I2 (en) | 2023-12-15 |
Family
ID=59714166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR22C1063C Active FR22C1063I2 (en) | 2016-08-19 | 2022-12-16 | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF HIV VIRUS INFECTION |
Country Status (42)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| KR102180740B1 (en) | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic compounds useful for prophylactic or curative treatment of HIV viral infection |
| AR112413A1 (en) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | SOLID FORMS OF AN HIV CAPSID INHIBITOR |
| AR112412A1 (en) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR |
| JP7083398B2 (en) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | Pyridine derivatives and their use for treating HIV infection |
| KR102587504B1 (en) * | 2018-02-16 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | Methods and intermediates for preparing therapeutic compounds useful for the treatment of retroviridae virus infections |
| US20210115061A1 (en) * | 2018-06-21 | 2021-04-22 | Drexel University | Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same |
| TW202425967A (en) * | 2018-07-16 | 2024-07-01 | 美商基利科學股份有限公司 | Capsid inhibitors for the treatment of hiv |
| BR112021001617A2 (en) * | 2018-08-09 | 2021-04-27 | VIIV Healthcare UK (No.5) Limited | replication inhibitors of the human immunodeficiency virus |
| JP7361766B2 (en) | 2018-09-14 | 2023-10-16 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | Inhibitor of human immunodeficiency virus replication |
| US11919897B2 (en) | 2018-09-20 | 2024-03-05 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| CR20210207A (en) | 2018-10-24 | 2021-09-02 | Viiv Healthcare Uk No 5 Ltd | Inhibitors of human immunodeficiency virus replication |
| ES2971987T3 (en) | 2018-10-24 | 2024-06-10 | Viiv Healthcare Uk No 5 Ltd | Inhibitors of human immunodeficiency virus replication |
| PT3870575T (en) | 2018-10-25 | 2023-05-12 | Viiv Healthcare Uk No 5 Ltd | Inhibitors of human immunodeficiency virus replication |
| JP7526174B2 (en) * | 2018-10-29 | 2024-07-31 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication - Patents.com |
| WO2020095176A1 (en) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3877387A1 (en) | 2018-11-05 | 2021-09-15 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3914604A4 (en) | 2019-01-25 | 2022-10-19 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| UY38559A (en) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS |
| JP7545414B2 (en) | 2019-04-30 | 2024-09-04 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | Human immunodeficiency virus replication inhibitors |
| RU2717101C1 (en) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Anellated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine-7-carboxamides - integrase inhibitors, methods for preparing and using thereof |
| RS65304B1 (en) * | 2019-06-19 | 2024-04-30 | Viiv Healthcare Uk No 5 Ltd | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
| WO2021064571A1 (en) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| ES2974657T3 (en) | 2019-10-01 | 2024-07-01 | Viiv Healthcare Uk No 5 Ltd | n-Substituted-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of human immunodeficiency virus replication |
| TW202128648A (en) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | Inhibitors of human immunodeficiency virus replication |
| WO2021070054A1 (en) | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP2023502530A (en) * | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ， インコーポレイテッド | Capsid inhibitors for HIV prevention |
| WO2021107066A1 (en) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| EP4067349A4 (en) * | 2019-11-29 | 2022-12-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof |
| CN116098917A (en) * | 2020-02-27 | 2023-05-12 | 河南真实生物科技有限公司 | Use of nucleoside compounds for treating coronavirus infectious diseases |
| US20230106880A1 (en) | 2020-03-06 | 2023-04-06 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112022017832A2 (en) | 2020-03-06 | 2022-11-01 | Viiv Healthcare Uk No 5 Ltd | HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| BR112022020933A2 (en) | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| CN116437958A (en) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | Method for identifying HIV patients susceptible to therapy with gp120 CD4 binding site directed antibodies |
| AU2022211056A1 (en) * | 2021-01-25 | 2023-07-20 | Brii Biosciences, Inc. | Combination therapy for hiv with adenosine derivative and capsid inhibitors |
| WO2022247942A1 (en) | 2021-05-28 | 2022-12-01 | 江苏恒瑞医药股份有限公司 | Pharmaceutically acceptable salt and crystal form of fused pyridine ring derivative and preparation method therefor |
| KR20230019059A (en) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | COMPOSITION FOR TREATING AND IMPROVING VIRAL DISEASE COMPRISING GLECHOMA GRANDIS (A.Gray) KUPRIAN. EXTRACT AS AN EFFECTIVE INGREDIENT |
| KR20230018690A (en) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | Composition for treating and improving viral disease comprising geranium koreanum kom. extract as an effective ingredient |
| EP4440701A1 (en) * | 2021-12-03 | 2024-10-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| KR20240117588A (en) | 2021-12-03 | 2024-08-01 | 길리애드 사이언시즈, 인코포레이티드 | Compounds for the treatment of HIV viral infection |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TWI843506B (en) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202402280A (en) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| KR20240061218A (en) | 2022-10-31 | 2024-05-08 | 주식회사 이보드 | Composite insulation and manufacturing method |
| US20240287124A1 (en) | 2023-01-30 | 2024-08-29 | Merck Sharp & Dohme Llc | Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors |
| CN116675675A (en) * | 2023-06-05 | 2023-09-01 | 北京康立生医药技术开发有限公司 | Preparation method of lenacipam intermediate compound serving as AIDS treatment drug |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DK0533833T3 (en) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorus prodrugs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU8294101A (en) | 2000-07-21 | 2002-02-05 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| ES2291477T3 (en) | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | FLUOROPIRROLIDINS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA. |
| AU2002334205B2 (en) | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| US20040186151A1 (en) | 2003-02-12 | 2004-09-23 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
| EP1628685B1 (en) | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| JP2007525511A (en) | 2004-02-27 | 2007-09-06 | シェーリング コーポレイション | Compounds as novel inhibitors of hepatitis C virus NS3 serine protease |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| ME03423B (en) | 2004-07-27 | 2020-01-20 | Gilead Sciences Inc | Phosphonate analogs of hiv inhibitor compounds |
| US8067587B2 (en) | 2005-07-28 | 2011-11-29 | Lenroc Company | Process for the production of monoalkali metal cyanurates |
| WO2007018998A2 (en) | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| CA2633252A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| WO2007120729A2 (en) | 2006-04-12 | 2007-10-25 | Merck & Co., Inc. | Pyridyl amide t-type calcium channel antagonists |
| US7647464B2 (en) | 2006-04-28 | 2010-01-12 | At&T Intellectual Property, I,L.P. | Methods, systems, and products for recording media to a restoration server |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| CN101702908A (en) | 2007-03-23 | 2010-05-05 | 麻萨诸塞州大学 | hiv-1 protease inhibitors |
| WO2009005677A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| SI2175857T1 (en) | 2007-07-12 | 2014-01-31 | Janssen R&D Ireland | Crystalline form of (e) 4-ss4-ss4-(2-cyanoethenyl)-2,6-dimethylphenylcaminoc-2-pyrimidinylcaminocbenzonitrile |
| WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
| AU2008317352A1 (en) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide T-type calcium channel antagonists |
| AU2008317353B2 (en) | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| JP5285709B2 (en) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | Human immunodeficiency virus replication inhibitor |
| CN102026996B (en) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | Pyridazine derivatives as factor XIA inhibitors |
| ES2623794T3 (en) | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermediates for the preparation of toll receptor modulators |
| AU2010217230B2 (en) | 2009-02-25 | 2012-05-10 | Bigtec Private Limited | Probes and primers for detection of Chikungunya |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| MX2012015097A (en) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Napht- 2 -ylacetic acid derivatives to treat aids. |
| TWI458711B (en) | 2010-07-02 | 2014-11-01 | Gilead Sciences Inc | Therapeutic compounds |
| CN102464654B (en) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | Antiviral compound |
| SI2688403T1 (en) | 2011-03-23 | 2017-08-31 | Trevena, Inc. | Opioid receptor ligands and methods of using and making same |
| MX2013012266A (en) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use. |
| US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (en) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | Antiviral compound |
| ES2608871T5 (en) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Tenofovir alafenamide hemifumarate |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| SG11201401189WA (en) | 2012-04-20 | 2014-09-26 | Gilead Sciences Inc | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| MX357940B (en) | 2012-12-21 | 2018-07-31 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. |
| US20140221378A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| TW201443037A (en) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | Therapeutic compounds |
| EP2943493B1 (en) | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| JP5941598B2 (en) | 2013-01-09 | 2016-06-29 | ギリアード サイエンシーズ， インコーポレイテッド | 5-membered heteroaryls and their use as antiviral agents |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| TWI694071B (en) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | Therapeutic compounds for treating a retroviridae viral infection |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| JP6466433B2 (en) | 2013-10-24 | 2019-02-06 | ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ | Inhibitors of human immunodeficiency virus replication |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP3186239B1 (en) * | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP6385584B2 (en) | 2014-12-24 | 2018-09-05 | ギリアード サイエンシーズ， インコーポレイテッド | Fused pyrimidine compounds for the treatment of HIV |
| TWI770552B (en) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | Quinazoline compounds |
| KR20180005195A (en) | 2015-04-23 | 2018-01-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | Inhibitors of human immunodeficiency virus replication |
| UY36649A (en) | 2015-04-23 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION |
| KR20240008398A (en) * | 2015-07-06 | 2024-01-18 | 길리애드 사이언시즈, 인코포레이티드 | Cot modulators and methods of use thereof |
| US10171985B1 (en) | 2015-07-22 | 2019-01-01 | Ginko LLC | Method and apparatus for data sharing |
| KR102180740B1 (en) | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic compounds useful for prophylactic or curative treatment of HIV viral infection |
| JOP20180009A1 (en) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | Hiv inhibitor compounds |
| UY37710A (en) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION |
| AR112412A1 (en) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR |
| AR112413A1 (en) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | SOLID FORMS OF AN HIV CAPSID INHIBITOR |
| JP7083398B2 (en) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | Pyridine derivatives and their use for treating HIV infection |
| KR102587504B1 (en) | 2018-02-16 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | Methods and intermediates for preparing therapeutic compounds useful for the treatment of retroviridae virus infections |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| TW202425967A (en) | 2018-07-16 | 2024-07-01 | 美商基利科學股份有限公司 | Capsid inhibitors for the treatment of hiv |
| JP2023502530A (en) | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ， インコーポレイテッド | Capsid inhibitors for HIV prevention |
| US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
-
2017
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/en active IP Right Grant
- 2017-08-17 CR CR20190084A patent/CR20190084A/en unknown
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/en active Pending
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/en active Active
- 2017-08-17 KR KR1020247014103A patent/KR20240070646A/en active Search and Examination
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/en active Active
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 PL PL17758388T patent/PL3347352T3/en unknown
- 2017-08-17 PT PT191781483T patent/PT3597646T/en unknown
- 2017-08-17 SI SI201730077T patent/SI3347352T1/en unknown
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/en active Search and Examination
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/en unknown
- 2017-08-17 MX MX2018012905A patent/MX369307B/en active IP Right Grant
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/en active
- 2017-08-17 UA UAA201901739 patent/UA121630C2/uk unknown
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/en not_active Application Discontinuation
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/en active Active
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/en active Active
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/en unknown
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/en active
- 2017-08-17 MA MA42795A patent/MA42795B1/en unknown
- 2017-08-17 PT PT17758388T patent/PT3347352T/en unknown
- 2017-08-17 SI SI201731404T patent/SI3597646T1/en unknown
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/en unknown
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/en active IP Right Grant
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/en unknown
- 2017-08-17 UY UY0001037367A patent/UY37367A/en not_active Application Discontinuation
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/en unknown
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/en unknown
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/en unknown
- 2017-08-17 ES ES19178148T patent/ES2954514T3/en active Active
- 2017-08-17 CN CN202010662665.4A patent/CN111793061A/en active Pending
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/en not_active Application Discontinuation
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/en active Application Filing
- 2017-08-17 ES ES17758388T patent/ES2746374T3/en active Active
- 2017-08-17 TW TW106127987A patent/TWI664966B/en active
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/en unknown
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/en active
- 2017-08-17 MA MA050673A patent/MA50673A/en unknown
- 2017-08-17 CA CA3021227A patent/CA3021227C/en active Active
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 TW TW109146483A patent/TW202138365A/en unknown
- 2017-08-17 TW TW108108262A patent/TWI715944B/en active
-
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-13 HK HK18116015.7A patent/HK1256904B/en unknown
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/en unknown
-
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/en unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/en unknown
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/en unknown
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/en unknown
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/en unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/en unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
-
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/en not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/en active Pending
-
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
-
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/en not_active Withdrawn
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/en unknown
- 2022-12-16 NO NO2022059C patent/NO2022059I1/en unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/en active Active
- 2022-12-22 CY CY2022039C patent/CY2022039I1/en unknown
-
2023
- 2023-01-05 LT LTPA2023501C patent/LTPA2023501I1/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/en unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1063I2 (en) | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF HIV VIRUS INFECTION | |
| MA45539A (en) | DIHYDROPYRANOPYRIMIDINES FOR THE TREATMENT OF VIRAL INFECTIONS | |
| MA45052A (en) | POLYNUCLEOTIDES CODING FOR JAGGED1 FOR THE TREATMENT OF ALAGILLUS SYNDROME | |
| MA50482A (en) | CYCLING DERIVATIVES OF SULFAMOYLARYLAMIDE AND THEIR USE AS MEDICINAL PRODUCTS FOR THE TREATMENT OF HEPATITIS B | |
| MA47719A (en) | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | |
| MA43811A (en) | BICYCLIC ARYLMONOBACTAM COMPOUNDS AND THEIR METHODS OF USE FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| MA54925A (en) | COMPOSITIONS FOR THE TREATMENT OF ACID-BASED DISORDERS | |
| MA55720A (en) | MULTIPLE THERAPY FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | |
| MA45999A (en) | ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B | |
| MA49576A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | |
| MA45226A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF OXALATE RELATED CONDITIONS | |
| MA45552A (en) | COMPOSITIONS FOR THE TREATMENT OF AMYLOSIS | |
| MA55218A (en) | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | |
| MA51613A (en) | POLYTHERAPY FOR THE TREATMENT OR PREVENTION OF CANCER | |
| MA54522A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | |
| MA52737A (en) | ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSES TYPE IV A | |
| MA46967A (en) | METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS | |
| MA43051A (en) | POLYTHERAPY FOR THE TREATMENT OF HCV | |
| MA45227A (en) | PEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS | |
| MA45492A (en) | VIRAL VECTORS FOR THE TREATMENT OF NEUROGENOUS BLADDER HYPERACTIVITY | |
| MA43812A (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ZIKA VIRUS INFECTION | |
| MA51570A (en) | POLYTHERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| MA51615A (en) | POLYTHERAPY FOR THE TREATMENT OR PREVENTION OF CANCER | |
| MA51614A (en) | POLYTHERAPY FOR THE TREATMENT OR PREVENTION OF CANCER | |
| MA51621A (en) | POLYTHERAPY FOR THE TREATMENT OR PREVENTION OF CANCER |